Review article · 1 Oct 2019
Conference abstractPublished 26 Aug 2020
Biosimilar Drug Development and Approval Process
Food and Drug Administration, Rockville, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Emphasis will be placed on a stepwise approach to provide analytical studies, biological characterization, preclinical and clinical testing of the proposed biosimilar product presented in the premarket applications.The sponsors of premarket applications must present analytical characterization, pharmacokinetic (PK), pharmacodynamic (PD) and comparative clinical studies to demonstrate that a proposed biosimilar product is highly similar to a licensed reference product.Discussions will be presented on Quality Systems approach to c-GMP’s for Biosimilar Applications (Design Controls, validation and verification studies, analytical similarity, manufacturing and effective total product life-cycle CMC strategy).Discussions will be presented on clinical aspects of proposed biosimilar product (Immunogenicity Assessment, Extrapolations & Interchangeability in conformance with specific recommendations described in the FDA’s guidance on biosimilar labeling) .Emphasis will be placed on Quality Risk Management approach to design of studies by providing oversight and objective review of risk-benefit analysis that guides the clinical use of the new biosimilar drug product by providing patients organized data and appropriate labeling information in support of the new drug’s intended clinical use
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 30 Sep 2024
Clinical Trials and Regulatory Approvals: Navigating the Drug Development Process
Research article · 24 Jun 2015
From Idea to Market: The Drug Design, Development & Approval Process
Conference abstract · 26 Oct 2015
CMC Consideration for Biosimilar Drug Development and Manufacturing Process
Perspective · 28 Dec 2024
Drug Regulation and Approval: Impact of Accelerated Processes in the COVID Era
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Kaiser J Aziz”
